Jump to content


Biomarker for Diffuse Scleroderma skin has been discovered!


Photo

Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial


  • Please log in to reply
No replies to this topic

#1 Jeannie McClelland

Jeannie McClelland

    Senior Gold Member

  • ISN Support Specialists
  • PipPipPipPipPipPipPipPipPipPip
  • 1,706 posts
  • Location:in the Rocky Mountains of the USA

Posted 29 April 2010 - 10:24 AM

Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. In addition to the well-known effect of bosentan in prevention of digital ulcers, the results of this study demonstrate that bosentan may also be effective at reducing skin fibrosis in patients with SSc. Annegret Kuhn Rheumatology, April 5, 2010 (Also see: Skin Fibrosis)
This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical
Jeannie McClelland
(Retired) ISN Director of Support Services
(Retired) ISN Sclero Forums Manager
(Retired) ISN Blog Manager
(Retired) ISN Assistant News Guide
(Retired) ISN Artist
International Scleroderma Network